A hidden weakness in deadly cancers could lead to powerful new treatments

A UCLA research team has identified a critical vulnerability in small cell cancers that have long resisted treatment. Aggressive tumors lacking the RB gene depend heavily on a protein called E2F3 for survival. Blocking E2F3 stopped tumor growth in laboratory models. The key finding: existing FDA-approved drugs may be able to target this same weakness, potentially accelerating development of new therapies.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton